Palatin Technologies, Inc.

Healthcare · Biotechnology · United States

Last price 5.0465 USD (Oct 30, 2026, 10:03 AM EDT) · Market cap 9.81M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. li...